A‐Fibers Mediate Cold Hyperalgesia in Patients with Oxaliplatin‐Induced Neuropathy

Cold hyperalgesia is a common side effect of oxaliplatin treatment; still, the pathophysiological and molecular mechanisms as well as the contribution of different primary afferent fiber systems are unclear. Therefore, patients with oxaliplatin‐induced acute neuropathy with (n = 6) and without (n = 7) cold hyperalgesia were tested by applying a preferential blockade of peripheral myelinated A‐fiber afferents in combination with quantitative sensory testing. Additionally, an interview‐based questionnaire assessed the severity of symptoms and the impact on daily activities.

[1]  M. Ohsawa,et al.  Oxaliplatin treatment changes the function of sensory nerves in rats. , 2016, Journal of pharmacological sciences.

[2]  C. Cleeland,et al.  A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. , 2014, Cancer research.

[3]  F. Mols,et al.  A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration , 2014, Supportive Care in Cancer.

[4]  D. Shibata,et al.  Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors , 2013, Supportive Care in Cancer.

[5]  V. Lemmens,et al.  Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Ghelardini,et al.  A TRPA1 antagonist reverts oxaliplatin-induced neuropathic pain , 2013, Scientific Reports.

[7]  E. Saad,et al.  Literature review and practical aspects on the management of oxaliplatin-associated toxicity. , 2012, Clinical colorectal cancer.

[8]  R. Treede,et al.  Quantitative Sensory Testing of Neuropathic Pain Patients: Potential Mechanistic and Therapeutic Implications , 2012, Current Pain and Headache Reports.

[9]  P. Grafe,et al.  Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current , 2012, Proceedings of the National Academy of Sciences.

[10]  G. Wasner,et al.  Topical high-concentration (40%) menthol-somatosensory profile of a human surrogate pain model. , 2011, The journal of pain : official journal of the American Pain Society.

[11]  M. Friedlander,et al.  Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. , 2011, The oncologist.

[12]  P. Grafe,et al.  Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. , 2010, Neurotoxicology.

[13]  R. Treede,et al.  Reference data for quantitative sensory testing (QST): Refined stratification for age and a novel method for statistical comparison of group data , 2010, PAIN®.

[14]  Cindy S Tofthagen.  Surviving chemotherapy for colon cancer and living with the consequences. , 2010, Journal of palliative medicine.

[15]  K. Hanada,et al.  Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives , 2010, Pharmaceutical Research.

[16]  P. Rougier,et al.  Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study , 2009, PAIN®.

[17]  G. Wasner,et al.  Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system. , 2007, European journal of cancer.

[18]  G. Sobue,et al.  Ataxic vs painful form of paraneoplastic neuropathy , 2007, Neurology.

[19]  F. Birklein,et al.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values , 2006, PAIN.

[20]  J. Grem,et al.  Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer , 2005, BMC Cancer.

[21]  R. J. Cersosimo.  Oxaliplatin-Associated Neuropathy: A Review , 2005, The Annals of pharmacotherapy.

[22]  T. Conroy,et al.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Ralf Baron,et al.  Topical menthol--a human model for cold pain by activation and sensitization of C nociceptors. , 2004, Brain : a journal of neurology.

[24]  M. Floeter,et al.  Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy , 2004, Muscle & nerve.

[25]  E. Gamelin,et al.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. , 2002, Seminars in oncology.

[26]  M. Benatar.  Neurological potassium channelopathies. , 2000, QJM : monthly journal of the Association of Physicians.

[27]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Meyer,et al.  Secondary hyperalgesia to punctate mechanical stimuli. Central sensitization to A-fibre nociceptor input. , 1999, Brain : a journal of neurology.

[29]  O. Bouché,et al.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Raymond,et al.  Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Marty,et al.  Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.

[32]  F. Lévi,et al.  Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.

[33]  R. Treede,et al.  Pain related cerebral potentials: late and ultralate components. , 1987, The International journal of neuroscience.

[34]  D. Burke,et al.  Fibre function and perception during cutaneous nerve block. , 1975, Proceedings of the Australian Association of Neurologists.

[35]  H. E. Torebjörk,et al.  Perceptual changes accompanying controlled preferential blocking of A and C fibre responses in intact human skin nerves , 1973, Experimental Brain Research.

[36]  M. Espié,et al.  Phase I study of oxaliplatin in patients with advanced cancer , 2004, Cancer Chemotherapy and Pharmacology.